Temperature and light requirements for growth of two diatom species (Bacillariophyceae) isolated from an Arctic macroalga

In the present study, two abundant epiphytic diatom taxa were isolated from the assimilation hairs of the brown macroalga Chordaria flagelliformis collected in the Arctic Kongsfjorden (Spitsbergen, Norway), established as unialgal cultures and their growth rates determined under controlled photon fluence rate and temperature conditions. Using morphological (light and scanning electron microscopy) and SSU rRNA gene data both isolates (ROS D99 and ROS D125) were identified as members of a Fragilaria–Synedropsis clade. The molecular data of ROS D99 and ROS D125 were not identical to any other published sequence. While ROS D99 has been identified as Fragilaria barbararum mainly due to the SEM characteristics, ROS D125 could not be definitely identified although morphological data speak for Fragilaria striatula. Both diatom species showed similar growth rates at all temperatures and photon fluence rates tested. They grew well between 0 and 15°C with optimum temperatures of 12–14°C, but did not survive 20°C. Therefore, compared to Antarctic diatoms both taxa from Kongsfjorden can be characterised as eurythermal organisms. Increasing photon fluence rates between 2 and 15 μmol m⁻² s⁻¹ were accompanied with an almost twofold increase in growth rates, but photon fluence rates >15 μmol m⁻² s⁻¹ did not further enhance growth pointing to low light requirements. From these data optimum, minimum and maximum photon fluence rates and temperatures for growth can be assessed indicating that both diatoms are well acclimated to the fluctuating environmental conditions in the Arctic habitat.     

Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma

Current treatment options for advanced metastatic melanoma are limited to experimental regimen that provide poor survival outcomes. Immunotherapy is a promising alternative and we recently reported a clinical trial in which 6 out of 19 patients enrolled had objective clinical responses to a fully autologous melanoma/dendritic cell vaccine. The mechanism of the vaccine is not well understood, but we hypothesized that general immunocompetence may be a determinant of clinical response. We therefore examined the immune status of an expanded series of 21 patients who displayed varying clinical responses to the melanoma/dendritic cell vaccine. Immunocompetence was assessed using in vitro assays of lymphocyte function: survival, proliferation and cytokine responses to mitogen stimulation as well as T-cell receptor zeta expression and lymphocyte subset analysis. Although lymphocytes from patients mostly performed comparably to age-matched and sex-matched controls, in some assays we identified significant differences between complete clinical responders and other patients, both before and following vaccination. Surprisingly, before vaccination, only lymphocytes from clinical responder patients showed impaired in vitro survival. Following vaccination, T lymphocyte survival improved and cells recovered their ability to produce the Th1-associated cytokines TNF and IFN-gamma in response to anti-CD3 stimulation in vitro. No increase in Th1 cytokine production was observed in lymphocytes from patients who experienced partial clinical responses or progressive disease. We conclude that, before vaccination, patients who go on to have complete responses have immune characteristics suggestive of high cell turnover and low Th1-associated cytokine production, and that these can be reversed with vaccination. These results have potential implications for future immunotherapeutic strategies.